Demonstrating Profitability for the Seventh Consecutive Year, mProve Health Moves Growing Team into New Headquarter Offices
WASHINGTON, DC – May 22, 2017, mProve Health, a leading provider of mobile technologies used by life science organizations to connect and engage patients with global clinical research studies, announces unprecedented 12-month growth and the addition of 25% more new pharmaceutical companies and CROs to its client base. With contracts for research studies at 18 of the top 20 pharmaceutical companies and more than 15,000 clinical research sites in over 60 countries engaged to enroll patients on mProve’s applications, the company is expanding. mProve Health recently made a strategic move into new, industrial- and tech-inspired, open-concept offices in the Washington, DC metro area. This comes following 16 new hires in the past 12 months and the establishment of a UK-based team in London.
Washington, D.C. (September 5, 2014) – mProve Health, a leader in providing mobile technology services to the life sciences sector, announces the addition of T. Hephner to its team. Hephner has joined mProve as Vice President of Business Development.
Mr. Hephner brings over 15 years of business development, sales and marketing experience to mProve Health. A co-founder of Praxis, a leading patient recruitment provider, and a seasoned veteran of the clinical research world, Mr. Hephner will bring these experiences to one of the fastest growing companies in the life sciences arena.
Mr. Hephner is joining the team during a period of major expansion by mProve. Since its founding in 2010, mProve has steadily grown into a leadership position in the mHealth field, with a focus on the use of mobile devices to create clinical study efficiencies in the areas of patient recruitment, retention and in the collection of patient-reported outcomes. With revolutionary products and applications that allow for usage of participants’ own mobile devices, mProve has emerged as an industry leader in patient engagement products via mobile platform and is leading the way in next generation clinical trials.